In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $52. The company’s shares closed yesterday at $43.
Livnat observed:
“We’d long seen 2018 Exparel guidance as conservative, and now management is finally raising ~6% at the midpoint to $320-325M.”
According to TipRanks.com, Livnat has 0 stars on 0-5 star ranking scale with an average return of -9.6% and a 43.1% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Jazz Pharmaceuticals, and Agile Therapeutics.
Currently, the analyst consensus on Pacira Pharmaceuticals is a Moderate Buy with an average price target of $50.30, a 17.0% upside from current levels. In a report released yesterday, Seaport Global also reiterated a Buy rating on the stock with a $53 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $47.55 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 633.8K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
